Share This Page
Drug Price Trends for BRIMONIDINE-TIMOLOL
✉ Email this page to a colleague
Average Pharmacy Cost for BRIMONIDINE-TIMOLOL
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| BRIMONIDINE-TIMOLOL 0.2%-0.5% | 00781-7186-75 | 5.74099 | ML | 2024-12-18 |
| BRIMONIDINE-TIMOLOL 0.2%-0.5% | 82182-0455-15 | 7.63564 | ML | 2024-12-18 |
| BRIMONIDINE-TIMOLOL 0.2%-0.5% | 00781-7186-85 | 7.63564 | ML | 2024-12-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Brimonidine-Timolol
Introduction to Brimonidine-Timolol
Brimonidine-timolol, a fixed-dose combination of the alpha-2 adrenergic agonist brimonidine and the beta-blocker timolol, is a widely used medication for the treatment of glaucoma and ocular hypertension. This combination is marketed under brand names such as Combigan and is also available in generic forms.
Efficacy and Safety
Studies have shown that brimonidine-timolol is highly effective in reducing intraocular pressure (IOP), a key metric in managing glaucoma. A comparative study between brimonidine 0.2% and timolol 0.5% demonstrated that both medications significantly reduced mean IOP from baseline levels, with brimonidine showing greater peak reductions and timolol showing greater trough reductions[1].
Market Size and Growth
The glaucoma treatment market, which includes brimonidine-timolol, is projected to grow significantly. By 2023, the global glaucoma treatment market was expected to reach approximately $3 billion, up from $2.4 billion in 2013. This growth is driven by the introduction of new fixed-dose combination products and an increasing prevalence of glaucoma due to an aging population[3].
Sales and Revenue
In the United States, the market for brimonidine-timolol ophthalmic solution had U.S. sales of approximately $392 million for the 12 months ending February 2023. This figure highlights the substantial demand for this medication in the U.S. market[4].
Cost-Effectiveness Analysis
A cost-effectiveness analysis comparing brimonidine-timolol (Combigan) with dorzolamide-timolol (Cosopt) in 12 countries showed that Combigan was more effective in lowering IOP to target levels. While the costs varied by country, Combigan was found to be either less costly or slightly more costly but more effective than Cosopt in several countries. The incremental cost per patient reaching a target IOP level was relatively low, ranging from $0.60 to $96, depending on the target IOP level and the country[5].
Pricing and Availability
The cost of brimonidine-timolol ophthalmic solution can vary depending on the pharmacy and the quantity purchased. For example, a 5-milliliter supply of the 0.2%-0.5% ophthalmic solution can cost around $183 to $207, with prices varying based on the pharmacy and any available discounts or coupons[2].
Generic and Brand Options
The market for brimonidine-timolol includes both brand-name and generic options. The brand-name version, Combigan, has faced competition from generic equivalents. For instance, Upsher-Smith Laboratories launched a generic version of brimonidine tartrate and timolol maleate ophthalmic solution, which is an AB-rated generic equivalent to Combigan[4].
Future Projections
Given the patent expiration of Combigan in 2022, the market is expected to see increased competition from generic versions, which could impact pricing. However, the overall demand for glaucoma treatments is expected to remain strong due to the growing prevalence of glaucoma. The introduction of new products and the aging population will continue to drive market growth, although the exact price projections may vary based on these factors[3][4].
Key Takeaways
- Efficacy: Brimonidine-timolol is highly effective in reducing intraocular pressure.
- Market Size: The global glaucoma treatment market is projected to reach $3 billion by 2023.
- Sales: U.S. sales for brimonidine-timolol ophthalmic solution were approximately $392 million for the 12 months ending February 2023.
- Cost-Effectiveness: Combigan is more effective and often cost-effective compared to other fixed-dose combinations.
- Pricing: Prices vary but a 5-milliliter supply can cost around $183 to $207.
- Generic Options: Generic equivalents are available, impacting the market dynamics post-patent expiration.
FAQs
1. What is the primary use of brimonidine-timolol ophthalmic solution? Brimonidine-timolol ophthalmic solution is primarily used to treat glaucoma and ocular hypertension by reducing intraocular pressure.
2. How effective is brimonidine-timolol in reducing intraocular pressure? Brimonidine-timolol significantly reduces mean intraocular pressure from baseline levels, with brimonidine showing greater peak reductions and timolol showing greater trough reductions[1].
3. What is the expected market size for glaucoma treatments by 2023? The global glaucoma treatment market is projected to reach approximately $3 billion by 2023[3].
4. How much does a typical supply of brimonidine-timolol ophthalmic solution cost? A 5-milliliter supply of the 0.2%-0.5% ophthalmic solution can cost around $183 to $207, depending on the pharmacy and any available discounts[2].
5. Are there generic versions of brimonidine-timolol available? Yes, generic versions of brimonidine-timolol ophthalmic solution are available, including an AB-rated generic equivalent to Combigan launched by Upsher-Smith Laboratories[4].
Sources
- Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily in patients with glaucoma or ocular hypertension. PubMed.
- Brimonidine/timolol ophthalmic Prices, Coupons, Copay Cards & Patient Assistance. Drugs.com.
- Glaucoma Treatment Market Value Projected to Hit $3 Billion by 2023. Glaucoma Today.
- Upsher-Smith Expands Ophthalmic Portfolio with Launch of Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution. Upsher-Smith.
- Cost-Effectiveness Analysis of the Fixed Combinations Brimonidine/Timolol and Dorzolamide/Timolol in 12 Countries. Invest. Ophthalmol. Vis. Sci.
More… ↓
